We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: rectal cancer
MedXY News
EnglishTag

rectal cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

AI Model Shows Moderate Accuracy for Predicting Complete Response After Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
AIartificial intelligencerectal cancer

AI Model Shows Moderate Accuracy for Predicting Complete Response After Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

By MedXY|Jun 8, 2026

A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer
Gastroenterologycancer surveillanceNonoperative Management

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer

By MedXY|May 8, 2026

Study finds 62% of rectal cancer patients on Watch and Wait receive optimal surveillance, with younger patients showing better adherence. Critical gaps occur in the first year, particularly in initial endoscopic/imaging exams and colonoscop

Rectal Cancer Accreditation Was Linked to Higher Hospital Volume Without More Care Fragmentation
General Surgeryaccreditationhospital volume

Rectal Cancer Accreditation Was Linked to Higher Hospital Volume Without More Care Fragmentation

By MedXY|May 8, 2026

A national difference-in-differences study found NAPRC accreditation was associated with modest growth in rectal cancer volume and stage I procedural volume, without evidence of increased care fragmentation.

The Bottom-Up Revolution: How New Surgical Techniques are Saving Lives and Lifestyles in Rectal Cancer
General Surgeryoncologyrectal cancer

The Bottom-Up Revolution: How New Surgical Techniques are Saving Lives and Lifestyles in Rectal Cancer

By MedXY|Mar 18, 2026

A groundbreaking North American trial reveals that the taTME ‘bottom-up’ surgical approach for rectal cancer offers a 93.7% three-year survival rate and allows 97% of patients to remain stoma-free, fundamentally changing the lan

Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer
GastroenterologyIrinotecanneoadjuvant therapy

Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer

By MedXY|Jan 14, 2026

The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r

A 30-Day Mortality Risk Score After Proctectomy for Rectal Cancer: What the NCDB Tells Us and How to Use It
General Surgeryrectal cancer

A 30-Day Mortality Risk Score After Proctectomy for Rectal Cancer: What the NCDB Tells Us and How to Use It

By MedXY|Dec 2, 2025

A validated NCDB-derived risk score using age, sex, race, comorbidity, stage, neoadjuvant therapy, length of stay and conversion identifies patients at markedly different 30-day mortality risk after proctectomy (0.8%–4.5%).

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial
Gastroenterologynon-operative managementorgan preservation

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

By MedXY|Nov 29, 2025

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Real-World Insights from an International Consortium
Oncologyclinical outcomesrectal cancer

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Real-World Insights from an International Consortium

By MedXY|Oct 4, 2025

This international multicenter study evaluates total neoadjuvant therapy (TNT) in routine clinical practice for stage II/III rectal adenocarcinoma, demonstrating varied regimen use and confirming TNT’s efficacy across treatment strategies.

Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial
Oncologychemoradiotherapyimmune checkpoint inhibitors

Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial

By MedXY|Oct 4, 2025

The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete res

Advancing Organ Preservation in Locally Advanced Rectal Cancer: Insights from the CAO/ARO/AIO-16 Phase 2 Trial
Clinical Updatesorgan preservationrectal cancer

Advancing Organ Preservation in Locally Advanced Rectal Cancer: Insights from the CAO/ARO/AIO-16 Phase 2 Trial

By MedXY|Oct 3, 2025

Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.

Short-Course Radiotherapy Plus Sintilimab and Chemotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the SPRING-01 Trial
Clinical Updatesclinical trialneoadjuvant therapy

Short-Course Radiotherapy Plus Sintilimab and Chemotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the SPRING-01 Trial

By MedXY|Oct 1, 2025

Adding sintilimab to short-course radiotherapy and chemotherapy significantly increased pathological complete response rates in locally advanced rectal cancer, with manageable safety.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities